Board member resigns at his request
OSLO, NORWAY – November 2, 2023: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces today that the board member Staffan Strömberg has resigned from the Board of Directors (“BoD”) at his request, due to high workload, with immediate effect.
"I am unable to fully participate in the board work as I would like due to my current workload. Therefore, I have chosen to end my assignment, creating an opportunity for someone who can wholeheartedly dedicate themselves to GA’s future development," Staffan Strömberg, board member of GA, explained.
"It is sad to have to leave the GA board because I believe that the company is on the threshold of establishing increased sales through the new distribution network that the management of the company has established. I am the CEO of a Swedish company that has begun preparations for a global launch of a new pharmaceutical drug. The launch preparations take up my focus and I have therefore decided to leave two board assignments, of which GA is one," explained Staffan Strömberg, board member of GA.
”We have great respect for Staffan Strömberg’s decision and on behalf of the Board I thank him for his valuable contribution to the work of the Board and wish all the best for the future,” comments Per Matsson, chairperson of Genetic Analysis.
According to GA’s articles of association, the BoD shall consist of a minimum of two and a maximum of seven members. When Staffan Strömberg has resigned, the BoD will consist of four members, thus fulfilling the requirements of the articles of association.
For more information, please contact:
Ronny Hermansen, CEO
E-mail: rh@genetic-analysis.com
About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics, molecular biology, and bioengineering.
For more general information: www.genetic-analysis.com
Stay updated on GA and sign up for more investor-related information: https://www.genetic-analysis.com/subscriptions/
Interested in reading more about GA's products? Please visit ga-map.com